Neuphoria Therapeutics (NEUP) Enterprise Value (2020 - 2026)
Neuphoria Therapeutics (NEUP) reported Enterprise Value of -$19.4 million for Q1 2026, down 13.82% year-over-year from -$22.5 million in Q1 2025, and up 12.81% on a QoQ basis from -$22.3 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 7 years of Enterprise Value data on file, last reported at -$19.4 million in Q1 2026.
- Quarterly Enterprise Value fell 13.82% year-over-year to -$19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.4 million (down 13.82% YoY) and the FY2025 annual result came in at -$14.3 million, down 13.33% from the prior year.
- Enterprise Value advanced to -$19.4 million in Q1 2026 per NEUP's latest filing, from -$22.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$4.3 million in Q4 2024 and bottomed at -$24.0 million in Q2 2022.
- The 5-year median for Enterprise Value is -$12.6 million (2024), against an average of -$13.4 million.
- The widest annual swing landed in 2024, when Enterprise Value soared 57.22%; it then plunged 412.13% in 2025.
- Tracing NEUP's Enterprise Value over 5 years: stood at -$24.0 million in 2022, then soared by 57.76% to -$10.2 million in 2023, then jumped by 57.22% to -$4.3 million in 2024, then sank by 412.13% to -$22.3 million in 2025, then advanced by 12.81% to -$19.4 million in 2026.
- Per Business Quant, the three latest NEUP Enterprise Value figures stand at -$19.4 million (Q1 2026), -$22.3 million (Q4 2025), and -$13.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | -19.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.40 Mn |
| Dec 31, 2025 | -22.28 Mn |
| Sep 30, 2025 | -13.73 Mn |
| Jun 30, 2025 | -14.29 Mn |
| Mar 31, 2025 | -17.00 Mn |
| Dec 31, 2024 | -4.34 Mn |
| Sep 30, 2024 | -8.08 Mn |
| Jun 30, 2024 | -12.61 Mn |
| Mar 31, 2024 | -8.43 Mn |
| Dec 31, 2023 | -10.15 Mn |
| Sep 30, 2023 | -8.14 Mn |
| Jun 30, 2023 | -12.20 Mn |
| Jun 30, 2022 | -24.04 Mn |
| Dec 31, 2021 | -29.48 Mn |
| Jun 30, 2021 | -22.28 Mn |
| Jun 30, 2020 | -3.00 Mn |